SEATTLE, WA, May 12, 2011 — Pacific Biomarkers, Inc. (PBI) (OTCBB: PBMC), a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, announced that representatives from the company will speak at the 2011 AAPS National Biotechnology Conference being held at the Hilton San Francisco Union Square in San Francisco, California on May 16-18. The AAPS National Biotechnology Conference is an annual event devoted to advancing health through innovations in biotherapeutics.
Amar A. Sethi, MD, PhD, Vice President of Research and Development, and Tonya K. Aggoune, Director of Project Services, are slated to present talks during a symposium titled “Ligand Binding Assay: Partnering and Synergies from Pharmaceutical and Diagnostic Industries.” Dr. Sethi’s talk is called “Ligand Binding Assay Instrumentation in the Diagnostic Industry” and Ms. Aggoune’s talk is called “Electronic Solution and Report Generation in the Diagnostic Industry.” The symposium will run from 1:30 pm – 4:00 pm on Tuesday, May 17.
About Pacific Biomarkers, Inc. (PBI)
Established in 1989, PBI provides biomarker laboratory services and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular and musculoskeletal diseases, diabetes, obesity, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI’s clients include many of the world’s largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing custom assays for novel clinical biomarkers, immunogenicity testing, mass spectrometry, and multiplex testing. PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol “PBMC.”
For more information about PBI, visit the company’s website at www.pacbio.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release includes forward-looking statements including, but not limited to, the following: results of business development activities; future growth; and the viability and acceptance of the Company’s biomarker services. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, the following: the Company’s ability to enter into contracts for its laboratory testing or biomarker services; client changes or early terminations of studies; variability in backlog; the success of marketing and business development efforts, and competitive factors; the Company’s ability to manage growth; and other risks and uncertainties set forth in periodic filings with the U.S. Securities and Exchange Commission (including Form 10-K for the year ended June 30, 2010).
Pacific Biomarkers, Inc.
Ron Helm, CEO
The Investor Relations Group